In August, Sanofi gave a first look at eagerly anticipated data from Phase III comparing its high-dose Fluzone vaccine with a standard jab. The data prompted Sanofi to talk up its chances of getting a label for superior efficacy data in people aged over 65, and this week it began making its case.
The discovery of a correlation between the flu vaccine and decreased risk of heart attack was met with skepticism earlier this year, particularly in light of GlaxoSmithKline's financial support of the study. But now, several months later, a new, more definitive analysis has identified the same trend.
While the government shutdown has cast doubt on the Centers for Disease Control and Prevention's (CDC) ability to manage the upcoming flu season, officials can take some solace from last year's efforts. Flu vaccine uptake levels in adults, kids and health workers all trended upward last year.
Congress' failure to find a budget compromise and subsequent government shutdown has left CDC without the staff to carry out many of its functions, including the seasonal influenza program.
The H7N9 vaccine may arrive too late and with too little manufacturing capacity to really help, a New Scientist feature warns.
Human immune systems were ill-prepared for the swine flu virus that spread across the globe in 2009. The lack of pre-existing immunity left people vulnerable but, researchers wondered, was everyone equally unprotected? Answering this question has led to a 'blueprint' for a universal flu vaccine.
The vaccine sector appears to be in good health. After coming through a period in which low profit margins and liability concerns deterred investment, EvaluatePharma now tips the sector to grow from $25 billion to $39 billion between 2012 and 2018. Yet, in some areas, old complaints can still be heard.
Evidence linking GlaxoSmithKline's swine flu vaccine to narcolepsy has mounted up this year, with new findings from Finland, Sweden and the United Kingdom emerging. Now, having previously knocked back compensation claims, the data has prompted the U.K. government to accept the link.
Massachusetts-based biotech Visterra is preparing to move its universal influenza therapy into the clinic.
Delivering a vaccine against an emerging pandemic flu strain requires developers to make a lot of quick decisions about dosing, use of adjuvants and other factors. With H7N9, however, China's success in limiting the virus' spread has given other countries more time to prepare.